**Author details**

Mariano Larzábal1 , Angel A. Cataldi1 \* and Daniel A. Vilte2

1 Institute of Biotechnology, IABIMO-CONICET, Center of Veterinary and Agronomical Research, National Institution of Agricultural Technology, Argentina

2 Institute of Pathobiology, IPVet-CONICET, Center of Veterinary and Agronomical Research, National Institution of Agricultural Technology, Argentina

\*Address all correspondence to: cataldi.angeladrian@inta.gob.ar

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**111**

*Human and Veterinary Vaccines against Pathogenic Escherichia coli*

enteropathogenicity in calves. Infection and Immunity. 1998;**66**:4560-4563

[8] Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, et al. Decreased shedding of *Escherichia coli* O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004;**22**:362-369. DOI: 10.1016/j.

vaccine.2003.08.007

2005;**46**:724-728

2009;**6**:155-161

fpd.2008.0080

[9] Van Donkersgoed J, Hancock D, Rogan D, Potter AA. *Escherichia coli* O157:H7 vaccine field trial in 9 feedlots in Alberta and Saskatchewan. The Canadian Veterinary Journal.

[10] Smith DR, Moxley RA, Peterson RE, Klopfenstein TJ, Erickson GE, Bretschneider G, et al. A two-dose regimen of a vaccine against type III secreted proteins reduced *Escherichia coli* in beef cattle in commercial feedlots. Foodborne Pathogens and Disease.

[11] Smith D, Moxley R, Peterson R, Klopfenstein T, Erickson G, Clowser S. A two-dose regimen of a vaccine against *Escherichia coli* O157:H7 type III secreted proteins reduced environmental transmission of the agent in a large-scale commercial beef feedlot clinical trial. Foodborne Pathogens and Disease. 2008;**5**:589-598. DOI: 10.1089/

[12] Smith DR, Moxley RA, Klopfenstein

TJ, Erickson GE. A randomized longitudinal trial to test the effect of regional vaccination within a cattle feedyard on *Escherichia coli* O157:H7 rectal colonization, fecal shedding, and hide contamination. Foodborne Pathogens and Disease. 2009;**6**:885-892.

DOI: 10.1089/fpd.2009.0299

[13] *E. coli* Vaccine Gets Full CFIA License | Canadian Cattlemen n.d. https://www.canadiancattlemen.ca/

*DOI: http://dx.doi.org/10.5772/intechopen.82835*

[1] Rivas M, Chinen I, Miliwebsky E, Masana M. Risk factors for Shiga toxinproducing *Escherichia coli*-associated human diseases. Microbiology Spectrum. 2014;**2**. DOI: 10.1128/ microbiolspec.EHEC-0002-2013

[2] Szu SC, Ahmed A. Clinical studies of *Escherichia coli* O157:H7 conjugate vaccines in adults and young children. Microbiology Spectrum. 2014;**2**. DOI: 10.1128/microbiolspec.

[3] Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC. Safety and Immunogenicity of *Escherichia coli* O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. The Journal of Infectious Diseases. 2006;**193**:515-521.

[4] Lu X, Skurnik D, Pozzi C, Roux D, Cywes-Bentley C, Ritchie JM, et al. A poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing *Escherichia coli*. MBio. 2014;**5**:e00974-e00914. DOI:

[5] DeVinney R, Stein M, Reinscheid D, Abe A, Ruschkowski S, Finlay BB. Enterohemorrhagic *Escherichia coli* O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated.

[6] Tzipori S, Gunzer F, Donnenberg MS, de Montigny L, Kaper JB,

Donohue-Rolfe A. The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic *Escherichia coli* infection. Infection and Immunity.

[7] Dean-Nystrom EA, Bosworth BT, Moon HW, O'Brien AD. *Escherichia coli* O157:H7 requires intimin for

EHEC-0016-2013

DOI: 10.1086/499821

10.1128/mBio.00974-14

Infection and Immunity. 1999;**67**:2389-2398

1995;**63**:3621-3627

**References**

*Human and Veterinary Vaccines against Pathogenic Escherichia coli DOI: http://dx.doi.org/10.5772/intechopen.82835*
